Group 1: Financial Performance - The company achieved an operating revenue of 2.65 billion yuan in 2024, representing a year-on-year growth of 9.84% [1] - The net profit attributable to the parent company was 234 million yuan, an increase of 7.34% compared to the previous year [1] - The company has a stable profit distribution policy and aims to maintain a steady cash dividend ratio to enhance shareholder returns [15] Group 2: Research and Development - The company emphasizes R&D investment as a core driver for growth, with plans to increase R&D spending to enhance overall competitiveness [2] - As of the end of 2024, the company has obtained 685 patents, with 580 being valid patents, and has established 183 national and industry standards [13] Group 3: International Business Expansion - International business revenues from 2022 to 2024 were 67 million yuan, 139 million yuan, and 214 million yuan, accounting for 2.50%, 5.78%, and 8.08% of total revenue, respectively [4] - The company is actively expanding into markets along the "Belt and Road" initiative, with a focus on establishing a unified management system for international operations [4] Group 4: Market Position and Strategy - The company recognizes the seasonal nature of its business, with the fourth quarter typically seeing higher revenue due to project acceptance and settlement [3] - The company is committed to digital transformation and innovation to strengthen its core business and improve operational efficiency [1][10] Group 5: Industry Outlook - The grain storage and logistics industry is expected to see increased demand due to national policies promoting modernization and technological advancements [6] - The company plans to integrate smart technologies into grain storage and logistics to enhance efficiency and sustainability [20]

Group 1: Financial Performance - In Q1 2025, the company's revenue increased by 48.85% year-on-year, while net profit decreased by 72.64% [4] - The company's operating income for 2024 was 652 million yuan, a decrease of 6.50% year-on-year, with net profit of 21.35 million yuan, down 56.23% [5] - The gross profit margin for the company's products was 14.66%, showing a decline compared to the same period last year [5] Group 2: Business Strategy and Focus - The company plans to use idle self-owned funds for financial management, aiming to improve the efficiency of idle funds without affecting normal operations [2] - The company will continue to focus on its main business, adapting strategies based on customer needs and industry developments [6] - The company is committed to expanding its product range and optimizing its application direction while integrating customer resources and supply chain advantages [8] Group 3: Market Trends and Opportunities - The wind power equipment sector is expected to enter a period of accelerated construction in 2025, driven by global consensus on renewable energy [5] - The power equipment sector is supported by government initiatives aimed at enhancing energy efficiency and carbon reduction [5] - The medical device market in China is experiencing rapid growth, driven by aging populations and increasing healthcare demands [5] Group 4: Challenges and Adjustments - The company faced a 17.44% year-on-year decline in revenue from wind power equipment components, while revenue from power equipment and medical devices grew by 9.51% [3] - The company is adjusting its product structure and business direction to maintain overall revenue stability amid fierce competition in the wind power industry [7] - Increased labor costs and rising shipping fees contributed to the decline in net profit despite revenue growth [4]

Group 1: Financial Performance - The company reported its first loss since its listing in 2015, with a total impairment provision of CNY 113.87 million due to prudence regarding goodwill [1] - In Q1 2025, the company achieved profitability with a year-on-year growth [2] - A cash dividend of CNY 0.50 per 10 shares (before tax) is proposed for Q1 2025, pending approval at the annual shareholders' meeting [5] Group 2: Business Strategy and Market Position - The company is focusing on enhancing its semiconductor and IoT business, with plans to strengthen R&D and market expansion to maintain competitive advantages [2][3] - The company has established a dual circulation production and marketing model to support global development and respond to international trade tensions [2] - The company aims to leverage its technological capabilities in both semiconductor packaging and IoT safety monitoring to drive revenue growth and profitability [6] Group 3: Challenges and Responses - The decline in revenue in 2024 was primarily due to the impact of geopolitical tensions on the overseas semiconductor business [2] - The company is actively monitoring changes in U.S. tariff policies and coordinating with partners to mitigate impacts [2] - To address market challenges, the company plans to enhance overseas market development and expand its market share in IoT equipment [4][5] Group 4: Product Development and Innovation - The company is launching new products in the semiconductor sector, including various laser cutting machines and customized models based on the 8230 technology platform [3] - The integration of AI and large model technologies is being actively pursued in product development [4] - The company has successfully developed a one-piece reverse planetary roller screw electric cylinder, targeting specific industry needs [7]

证券代码： 002755 证券简称：奥赛康 北京奥赛康药业股份有限公司 投资者关系活动记录表 | 投资者关系活动 | □特定对象调研 □ 分析师会议 | | --- | --- | | 类别 | 媒体采访 业绩说明会 □ √ | | | 路演活动 □ 新闻发布会 □ | | | □ 现场参观 | | | □ 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 投资者网上提问 | | 人员姓名 | | | 时间 | 2025 年 5 月 9 日 (周五) 下午 15:00~17:00 | | 地点 | 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net） | | | 采用网络远程的方式召开业绩说明会 | | 上市公司接待人 | 1、董事长 陈庆财 | | 员姓名 | 2、总经理、董事会秘书 马竞飞 | | | 3、财务总监 韩涛 | | | 4、独立董事 林振兴 投资者提出的问题及公司回复情况 | | | 公司就投资者在本次说明会中提出的问题进行了回复： | | | 1、请问截止到 2025 年 5 月 8 日股东人数是多少？ | | | 回复：尊敬的投资者，您好！公司不掌握 ...

投资者关系活动记录表 编号：PH20250509 投资者关系活 动类别 □特定对象调研 □分析师会议 □媒体采访 ■业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 （投资者电话交流会） 参与单位名称 及人员姓名 公司 2024 年度业绩说明会采用网络远程方式进行，面向全体投资者 时间 2025 年 5 月 9 日（星期五）下午 15:00 至 17:00 地点 深圳证券交易所"互动易平台"http://irm.cninfo.com.cn"云访谈" 栏目 上市公司参与 人员姓名 董事长：夏信德先生 总裁：甄少强先生 董事会秘书：鲁宏力先生 财务负责人：潘丽女士 独立董事：宋小宁先生 保荐代表人：徐焕杰先生 投资者关系活 动主要内容介 绍 公司于 2025 年 5 月 9 日下午 15:00 至 17:00 在互动易"云访 谈"（http://irm.cninfo.com.cn）举行了 2024 年度业绩网上说明 会。本次业绩说明会采用网络方式举行，公司与投资者交流的主要内 容如下： 1、高管您好。请问贵公司本期财务报告中，盈利表现如何？谢 谢。 答：您好！2024 年，电池产业竞争加剧，虽劣质产能及低 ...

证券代码：002629 证券简称：仁智股份 浙江仁智股份有限公司 投资者关系活动记录表 编号：2025-001 | | □特定对象调研 □分析师会议 | | --- | --- | | 投资者关系 活动类别 | □媒体采访 业绩说明会 | | | □新闻发布会 □路演活动 | | | □现场参观 | | | □其他（请文字说明其他活动内容） | | 活动参与人员 | 线上参与公司 2024 年度网上业绩说明会的全体投资者 | | 时间 | 2025 年 5 月 9 日 15:00-17:00 | | 地点 | 价值在线（https://www.ir-online.cn/）网络互动 | | 上市公司 | 董事长（代） 梁昭亮先生 | | | 董事兼总裁 陈曦先生 | | 接待人员姓名 | 独立董事 吴申军先生 | | | 财务总监 黄勇先生 | | | 副总裁兼董事会秘书 王晶女士 | | 形式 | 投资者线上文字交流 | | 投资者关系活动主 | 问题 1：从年报看新能源电力工程业务受政策影响比较 | | | 大，在 2025 年准备采取什么措施来应对？ | | | 回复：尊敬的投资者您好，公司新能源电力工 ...

森霸传感科技股份有限公司 投资者关系活动记录表 证券代码：300701 证券简称：森霸传感 编号：2025-001 投资者关系 活动类别 □特定对象调研 □分析师会议 □媒体采访 ■业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 ___________________ 参与单位名称 及人员姓名 投资者网上提问 时间 2025 年 5 月 9 日（星期五）15:00—17:00 地点 公司通过价值在线（www.ir-online.cn）采用网络远程的方式召开业绩说明 会 上市公司 接待人员姓名 公司董事长单森林先生、总经理邓婧女士、财务负责人兼董事会秘书邹洋 先生、独立董事王征女士 投资者关系活 动主要内容介 绍 投资者提出的问题及公司回复情况： 1、问: 请介绍下公司 2024 年度的生产经营情况？ 答：2024 年度，公司实现营业收入 44,637.10 万元，同比增长 51.33%， 归属于上市公司股东的净利润 3,941.33 万元，同比下降 30.17%，归属于上 市公司股东的扣除非经常性损益的净利润 5,316.74 万元，同比上升 51.34%。 营业收入的增长主要系并表格林通、以及下游 ...

Group 1: Company Performance and Market Outlook - The company has no current plans for share reduction despite market fluctuations [2] - The domestic market for G-CSF reached nearly 10 billion RMB in 2022, indicating significant demand [9] - The company expects to ship approximately 40,000 units of overseas orders in 2025, including shipments to the U.S. market [3] Group 2: Product Development and Clinical Trials - F-652 is undergoing clinical trials with a focus on alcohol-related liver disease, with ongoing internal strategy discussions to mitigate risks [22] - The F-627 product is expected to launch in the U.S. around June 2025, with a projected shipment of 270,000 units [17] - The company anticipates that the new cell toxic production line in Hefei will be completed as scheduled [2] Group 3: Investor Relations and Communication - Investors expressed concerns about the company's communication effectiveness, particularly regarding the management's responsiveness to shareholder inquiries [5] - The company acknowledges the need for improved investor relations and plans to enhance communication strategies [21] - The management is committed to ensuring that the stock price reflects the company's true value and will work on investor engagement [21] Group 4: Financial Management and Market Strategy - The company reported a 13.55% decrease in net profit due to lower gross margins from synthetic biological products and the impact of centralized procurement [20] - The company is focusing on maintaining competitive pricing and expanding market share in the vitamin B5 sector despite current price pressures [20] - The company plans to leverage its strengths in quality and production capacity to sustain its market leadership in the vitamin sector [20]

Industry Overview - The pharmaceutical industry is a strategic pillar for national health and economic development, increasingly gaining public and government attention [2][3] - The demand for healthcare is experiencing rigid growth due to economic development, improved living standards, and demographic changes [2] Company Performance - In Q1 2025, the company reported a revenue increase of 27.83% year-on-year, amounting to 27.22 million yuan, and a net profit increase of 197.23%, totaling 10.22 million yuan [3][12] - The growth is attributed to expanded sales channels and successful partnerships with major chain pharmacies [3][12] Product and Market Strategy - The company specializes in the research, production, and sales of traditional Chinese medicine (TCM), focusing on stable and effective formulations [3][5] - The company has over 70 approved products across various categories, including throat, cold, orthopedics, and gynecology [9][11] - The company is adapting to the normalized centralized procurement model, which has covered over 20 product groups and 95 varieties [3][5] Internal Control and Compliance - The company emphasizes internal control and compliance, enhancing management through dedicated personnel and electronic process controls [12] - Recent improvements include the establishment of a compliance culture and the introduction of a multi-tiered governance mechanism [12] Future Outlook - The company plans to leverage its "Guangdong Old Brand" title to enhance brand recognition and expand market share through strategic partnerships [12] - The focus will be on optimizing product structure and enhancing clinical and scientific value to improve market positioning [7][12] Financial Health - As of Q1 2025, the company reported total assets of 812.64 million yuan and a low debt-to-asset ratio of 10.89%, indicating strong liquidity [12]

证券代码：300793 证券简称：佳禾智能 佳禾智能科技股份有限公司投资者关系活动记录表 编号：2025003 | | □分析师会议 | □特定对象调研 | | --- | --- | --- | | | □媒体采访 业绩说明会 | | | 投资者关系活动类别 | □新闻发布会 □路演活动 | | | | □现场参观 | | | | □其他 | | | 参与单位名称及人员姓 | 详见附件名单 | | | 名 | | | | 时间 | 2025 年 05 月 09 日 | | | 地点 | 在进门财经网络交流平台以网络电话或文字形式交流 | | | 上市公司接待人员 | 董事长严帆先生、独立董事何华明先生、副总经理兼董事会秘书夏 | | | | 平先生、财务总监刘东丹先生 | | | 投资者关系活动主要内 | 电话会议和网络文字互动交流的主要内容： 1、基于当前行业发展态势，公司未来 2-3 年的核心战略定位 | | | | 如何规划？在平衡短期业绩与长期战略目标时，如何量化关键指 | | | | 标并保障战略的有效落地？ | | | 容介绍 | 答：2024 年 ODM 厂商市场价格竞争愈发激烈，同质化现象 ...